Ramatroban

Source: Wikipedia, the free encyclopedia.
Ramatroban
Clinical data
Trade namesBaynas
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral (tablets)
ATC code
  • None
Legal status
Legal status
  • Rx-only (JP)
Identifiers
  • 3-((3R)-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic acid
JSmol)
SMILES
  • C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
  • InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
  • Key:LDXDSHIEDAPSSA-OAHLLOKOSA-N

Ramatroban (

thromboxane receptor antagonist.[2]

It is also a

DP2 receptor antagonist.[3]

It is indicated for the treatment of coronary artery disease.[4] It has also been used for the treatment of asthma.[5]

It has been suggested that ramatroban, by modulating

SARS-Cov-2.[citation needed] Hence, ramatroban, that has been used for the treatment of allergic rhinitis in Japan for the past two decades with a well established safety profile, merits investigation as a novel immunotherapy for the treatment of COVID-19 disease, although no clinical trial has yet been conducted.[6]

Ramatroban was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer Yakuhin then marketed by Kyorin Pharmaceutical and Nippon Shinyaku Co., Ltd. under the trade name Baynas.

References

  1. ^ "Ramatroban (compound)". PubChem. National Center for Biotechnology Information. Retrieved 22 June 2019.
  2. S2CID 10016709
    .
  3. PMID 18837743
    .
  4. PMID 2260140
    .
  5. PMID 8950952
    .
  6. PMID 32696108
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ramatroban&oldid=1244064175"